Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1693
This examiner grants 58% of resolved cases
Stephanie Lauren Sullivan is an examiner in Tech Center 1600 and Art Unit 1600. The data shows 73 resolved cases for this examiner. The allowance rate is 57.5 percent, which represents the frequency of grants among those resolutions. Practitioners should consider the interview lift of 40.3 percent when developing a strategy. This lift indicates that the probability of success increases when an interview is conducted. The 40.3 percent figure is a comparison to the baseline allowance rate of 57.5 percent.
The median time to allowance is 1313 days. This 1313-day period is the duration from the initial filing to the final grant. Art Unit 1600 is the specific group where these 73 resolved cases were processed. Tech Center 1600 provides the broader organizational context for the examiner's work. Practitioners can use these metrics to set expectations for the length of the prosecution cycle. The data provides a basis for evaluating the impact of direct communication with the examiner during the patent application process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18287711 | AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18186290 | IN VITRO GENETIC DISEASE MODEL CELL AND METHOD FOR PRODUCING THE SAME | Final Rejection | RICOH COMPANY, LTD. |
| 18506430 | REPRESSOR PROTEINS FOR GENE REGULATION AND CRISPR INTERFERENCE | Non-Final OA | Georgia Tech Research Corporation |
| 17627606 | SIRNA SEQUENCES TARGETING THE EXPRESSION OF HUMAN GENES JAK1 OR JAK3 FOR A THERAPEUTIC USE | Final Rejection | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | Final Rejection | The Regents of the University of California |
| 18015102 | NUTRITIONAL COMPOSITION COMPRISING MIR-3141 | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18577964 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC PAIN AND FOR RETROGRADE TRANSDUCTION OF NEURONS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18279440 | IN VIVO DNA ASSEMBLY AND ANALYSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18177068 | LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Final Rejection | Vanderbilt University |
| 18283242 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTIC SYSTEM | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 16966851 | COMPOSITIONS AND METHODS FOR INDUCING TRIPARTITE MOTIF-CONTAINING PROTEIN 16 (TRIM16) SIGNALING | Final Rejection | University of Washington |
| 17059692 | MODIFIED NUCLEIC ACID INHIBITING MICRO RNA, AND USE THEREOF | Final Rejection | Korea University Research and Business Foundation |
| 18556944 | COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17615520 | RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF | Final Rejection | AMGEN INC. |
| 18978602 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18001813 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17279542 | 2' FANA MODIFIED FOXP3 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | Non-Final OA | The Children's Hospital of Philadelphia |
| 17426059 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Final Rejection | KSQ Therapeutics, Inc. |
| 17348876 | RNA ENCODING A PROTEIN WITH A HETEROLOGOUS SIGNAL PEPTIDE | Final Rejection | Versameb AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy